Brind.
  1. Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics.

DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols.

1 report, 1 independent Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

DaVita is starting an operational pilot for Vafseo, and Akebia expects IRC to operationalize the Vafseo protocols.

Who's involved

What this event is mainly about
Akebia Therapeutics (United States)DaVitaIRC

How it developed

Newest first. Tap a step to see who reported it.
  1. Akebia Therapeutics conducted a study within DaVita clinics on August 4, 2025.Sub-event
  2. Operational pilot for Vafseo involving DaVita and IRC has begun.1 source

Keep exploring

Part of

Akebia Therapeutics is providing Vafseo for kidney disease treatment, which Innovative Renal Care has made available across all clinics. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAkebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million; T